SCHEMBL680604

SCHEMBL680604

CCOC(=O)c1cc(C)cn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
GABRA2 P47869 1/20 0.52
GABRB2 P47870 1/20 0.52
CHRNA7 P36544 3/20 0.50
LMNA P02545 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
TP53 P04637 2/20 0.45
KDM4E B2RXH2 3/20 0.44
GAA P10253 2/20 0.44
MAPK1 P28482 2/20 0.44
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679127 0.86 MAPT (0.61) ALDH1A1GABRA2GABRB2LMNANPC1
SCHEMBL679241 0.82 LMNA (0.57) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL21776538 0.81 MAPK1 (0.50) ALDH1A1CHRNA7LMNAMEN1KMT2A
SCHEMBL30388175 0.80 GABRA2 (0.50) ALDH1A1GABRA2GABRB2LMNANPC1
SCHEMBL680906 0.78 ALDH1A1 (0.46) ALDH1A1GABRA2GABRB2LMNANPC1
SCHEMBL23071325 0.78 GABRA2 (0.51) ALDH1A1GABRA2GABRB2CHRNA7LMNA
SCHEMBL23146924 0.77 MEN1 (0.52) ALDH1A1GABRA2GABRB2CHRNA7LMNA
SCHEMBL1260172 0.77 ALDH1A1 (0.80) ALDH1A1GABRA2GABRB2CHRNA7LMNA
SCHEMBL14969231 0.77 CMA1 (0.52) GABRA2GABRB2
SCHEMBL28525283 0.75 KMT2A (0.56) ALDH1A1GABRA2GABRB2CHRNA7LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762392-B1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO LTD (KR) 2024-05-15 EP disclosed
US-11447500-B2 Thienopyridine derivatives and pharmaceutical composition comprising same WELLMARKER BIO CO., LTD. (KR) 2022-09-20 US disclosed
US-20220288043-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO, LTD. (KR) 2022-09-15 US disclosed
CN-111295386-B Thienopyridine derivatives and pharmaceutical compositions containing the same 伟迈可生物有限公司 2022-09-06 CN disclosed
US-20210317133-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO., LTD. (KR) 2021-10-14 US disclosed
US-20210317133-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO., LTD. (KR) 2021-10-14 US disclosed
CN-111295386-A Thienopyridine derivatives and pharmaceutical compositions containing the same 伟迈可生物有限公司 2020-06-16 CN disclosed
WO-2019182274-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO., LTD. (KR) 2019-09-26 WO disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11447500-B2 Thienopyridine derivatives and pharmaceutical composition comprising same MAP4K5, MAP4K2, MAP3K9 ALDH1A1 2254/4885GABRA2 2430/4885GABRB2 2799/4885
US-20210317133-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME MAP4K5, MAP4K2, MAP3K9 ALDH1A1 2254/4885GABRA2 2430/4885GABRB2 2799/4885
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF ABL1, MAP4K2, MAP3K20 ALDH1A1 2255/4885GABRA2 2342/4885GABRB2 1695/4885
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC ALDH1A1 1450/4885GABRA2 3688/4885GABRB2 2418/4885
US-20220288043-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME PRKACA, MAP4K5, MAPKAPK5 ALDH1A1 2359/4885GABRA2 3041/4885GABRB2 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.